clinical trial · NCT07759154
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase3·recruiting·n = 80
Attention-deficit/Hyperactivity DisorderEmotional DysregulationCentanafadine XR
brief summary
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
started
Sep 1, 2026
primary completion
May 27, 2027
completion
May 27, 2027
last updated
Sep 14, 2026
official title
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol